

PTO/SB/08A (08-00)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>Substitute for form 1449</b>  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) <b>Sheet 1 of 3</b>	<b>Application Number</b>	10/697,840
	<b>Filing Date</b>	October 30, 2003
	<b>First Named Inventor</b>	Wynn et al.
	<b>Group Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	MCP-5021

**U.S. PATENT DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
KG		5,374,659		Gowan, Jr.	12-20-1994	
		4,788,220		Mody et al.	11-29-1988	
		4,975,465		Motola et al.	12-04-1990	
		5,183,829		Caldwell	2-02-1993	
		5,527,545		Santus et al.	6-18-1996	
		4,221,778		Raghunathan	9-09-1980	
		4,847,077		Raghunathan	7-11-1989	
		6,001,392		Wen et al.	12-14-1999	
		4,906,478		Valentine et al.	3-06-1990	
		5,275,822		Valentine et al.	1-04-1994	
		6,103,260		Luber et al.	8-15-2000	
		4,279,926		Bruzzese et al.	7-21-1981	

**FOREIGN PATENT DOCUMENTS**


Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				
KG		WO	96/01628	A1	Recordati S.A. Chemical and Pharmaceutical Company	1-25-1996		
KG		WO	97/41839	A1	F.H. Faulding & Co. Limited	11-13-1997		

Examiner Signature	<i>Kahn</i>	Date Considered	1-15-06
-----------------------	-------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Project of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 2 of 3	<b>Application Number</b>	10/697,840
	<b>Filing Date</b>	October 30, 2003
	<b>First Named Inventor</b>	Wynn et al.
	<b>Group Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	MCP-5021

## U.S. PATENT DOCUMENTS

Examiner Initials	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear
		Number	Kind Code <sup>2</sup> (if known)			
K6		4,873,231		Smith	10-10-1989	
		5,424,075		Daher et al.	6-13-1995	
		5,510,385		Stroppolo et al.	4-23-1996	
		5,374,659		Gowan, Jr.	12-20-1994	
		5,621,005		Gowan, Jr.	4-15-1997	
		5,409,907		Blase et al.	4-25-1995	
		4,752,580		Downs	6-21-1988	
		3,485,719		Rogovin	12-23-1969	
		2002/0031552	A1	McTeigue et al.	3-14-2002	
		6,197,347	B1	Jan et al.	3-06-2001	
K6		4,762,709		Sheumaker	8-09-1988	
		4,859,461		Chow et al.	8-22-1989	

## FOREIGN PATENT DOCUMENTS


Examiner Initials	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document mm-dd-yyyy	Pages, Columns, Lines, where relevant passages or relevant figures appear	T <sup>4</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup>				

Examiner Signature	<i>Katma</i>	Date Considered	1-18-06
-----------------------	--------------	--------------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS, SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450



PTO/SB-03A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Substitute for form 1449a <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary) Sheet 3 of 3	<b>Application Number</b>	10/697,840
	<b>Filing Date</b>	October 30, 2003
	<b>First Named Inventor</b>	Wynn et al.
	<b>Group Art Unit</b>	
	<b>Examiner Name</b>	
	<b>Attorney Docket Number</b>	MCP-5021

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS			
Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
KG		Ameer, B., et al., Ann. Int. Med. 82, pp. 202-209 (1977)	
		USP 23 (1995) pp. 788	
		USP 24, 2000 Version, 19-20 and 856-857 (1999)	
		Lieberman, Herbert A. and Lachman, Leon, "Pharmaceutical Dosage Forms: Tablets, Volume 3, pp. 73-117 and 119-221 (1982)	
		Setty, Chitrati et al., "Development and in vivo evaluation of multiparticulate sustained release formulation of diltizem hydrochloride using ethylcellulose and cellulose acetate phthalate," Indian Drugs 35(4) April 1998, pp. 195-199	
		Walter, K., et al., "Pharmacokinetics of ibuprofen following a single administration of a suspension containing enteric coated microcapsules," Arzneim-Forsch/ Drug Res. 45 (II), Nr. 8 (1995), pp. 886-890	
		Kurumaddail, K.R. et al., "Preparation and evaluation of sustained release ibuprofen beads," Drug Development and Industrial Pharmacy, 20(17), (1994) pp. 2659-2669	
		BELLAMY N. (Reprint) ET. AL: "A comparative-analysis of two dosing strategies of Flurbiprofen in Rheumatoid-Arthritis-An Application of Sequential Trial Design" Clinical and Investigative Medicine-Medecine Clinique ET Experimentale, (1988) Vol. 11, No. 6, PP. 441-445., XP00901716	
		BLACK, P. ET. AL.: "A randomized, double-blind, placebo-controlled comparison of the analgesic efficacy, onset of action, and tolerability of ibuprofen arginate and ibuprofen in postoperative dental pain" CLINICAL THERAPEUTICS, Vol. 24, No. 7, 2002, pages 1072-1089, XP002254117	
		GREBE, W. ET. AL.: "A multicenter, randomized, double-blind, double-dummy, placebo-and active-controlled, parallel-group comparison of diclofenac-K and ibuprofen for the treatment of adults with influenza-like symptoms" CLINICAL THERAPEUTICS, Vol. 25, No. 2, February 2003 (2003-02), pages 444-458, XP001155030	
		MEHLISCH, D.R.: "Ketoprofen, ibuprofen and placebo in the treatment of primary dysmenorrhea: a double-blind crossover comparison" J. Clin Pharmacol., Vol. 29, No.12, December 1988 (1988-12), pages s29-33, XP009017179	
		MEHLISCH, D.R.: "Double-blind crossover comparison of ketoprofen, naproxen, and placebo patients with primary dysmenorrhea" CLINICAL THERAPEUTICS, Vol 12, No 5, 1990, pages 398-409, XP009017199	
KG		PALMISANO, G. P. ET AL: " Double-blind crossover comparison of ketoprofen, ibuprofen, and placebo in the treatment of patients with primary dysmenorrhea" ADVANCES IN THERAPY, VOL. 5, NO. 4, 1988, pages 128-137 XP009017375	

Examiner Signature	<i>Kat Mc</i>	Date Considered	1-18-06
--------------------	---------------	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231.  
DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**SUBMISSION UNDER MPEP 609 D**

Page 1 of 1

<b>Application Number</b>	10/697,840
<b>Filing Date</b>	October 30, 2003
<b>First Named Inventor</b>	Wynn et al.
<b>Group Art Unit</b>	
<b>Examiner Name</b>	
<b>Attorney Docket Number</b>	MCP-5021

## U.S. PATENT DOCUMENTS


[illegible]

## FOREIGN PATENT DOCUMENTS

[illegible]

## OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

[illegible]

Examiner Signature		Date Considered	1.18.2006
-----------------------	---	--------------------	-----------

Examiner Signature		Date Considered	1.18.2006
-----------------------	---	--------------------	-----------